Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC).
Julie E. Bauman(George Washington University), Jennifer R. Grandis(University of California, San Francisco), Gordon B. Mills(The University of Texas MD Anderson Cancer Center), Antonio Jimeno(University of Colorado Cancer Center), Tanya J. Rath(University of Pittsburgh), William E. Gooding(UPMC Hillman Cancer Center), Faye M. Johnson(The University of Texas MD Anderson Cancer Center), Jason Kass(Brigham and Women's Hospital), Umamaheswar Duvvuri(City University of New York), John T. Flaherty(Johns Hopkins University), Malabika Sen(University of Pittsburgh Medical Center), Neil D. Gross(The University of Texas MD Anderson Cancer Center), John I. Song, Fred R. Hirsch(Tisch Hospital), Natanya I Pollock(University of Pittsburgh), Robert L. Ferris(University of Pittsburgh), Lin Wang(First Affiliated Hospital of Bengbu Medical College), Wendell G. Yarbrough(University of North Carolina at Chapel Hill), Seungwon Kim(UPMC Hillman Cancer Center), Jonas T. Johnson(University of Pittsburgh)
Cited by 5
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k